Canaccord lowered the firm’s price target on Adicet Bio to $19 from $21 and keeps a Buy rating on the shares. The firm noted the company is shifting its focus to autoimmune diseases and lowered its target to reflect a delayed pivotal trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACET: